Nektar Therapeutics (NASDAQ:NKTR)
CAPS Rating:
A biopharmaceutical company which develops breakthrough products that make a difference in patients' lives. It creates differentiated, innovative products by applying its platform technologies to established or novel medicines.
RSS Headlines
Fool UK
Recs
Because Pfizer want to stop sell the product(inulin inhaler) with NKTR, and the stock got plunge down hard by about 25%. But it will search for another partner to continue sell the product. It might be down for awhile, but I will come back up.